Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Royce Labs seeking court order to allow generic captopril marketing in suit v. Bristol-Myers Squibb.

Executive Summary

ROYCE CAPTOPRIL ANDA APPROVAL HINGES ON COURT RULING in a patent infringement suit brought by Capoten innovator Bristol-Myers Squibb. In an Aug. 11 emergency motion filed in response to Bristol's Aug. 4 suit, Royce Labs asks the Miami federal court to order Royce's captopril ANDA effective immediately. The patent suit brought by Bristol under the Waxman/Hatch Act triggers a 30-month stay of approval on the ANDA that can be lifted only by court order.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel